(RV5), reported G. Frank Liu, PhD, and his associates at Merck in Kenilworth, N.J.
The researchers discovered this by analyzing data from five clinical trials of RV5 at both the individual and aggregated population level. Also, by looking at immunogenicity measures and case status of individuals from phase 2 and 3 trials of RV5, they found that “higher PD3 G1 SNA titers are associated with lower odds of contracting any [rotavirus gastroenteritis].”
Read more at (Hum Vaccin Immunother. 2017.).